|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02563 BIOSTAR PHARM-B
Nominal 
3.720 -0.010 (-0.268%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 36,635 | 147.760% | 33,364 | 71,866 | 66,635 | 32,820 |
| Cost of Sales | (2,556) | 145.715% | -- | -- | (19,810) | (8,940) |
| Gross Profit | 34,080 | 147.915% | -- | -- | 46,825 | 23,880 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (209) | -- | (23,062) | (89) | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (26,596) | -50.787% | (131,435) | (143,777) | (189,644) | (160,511) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (26,596) | -50.787% | (131,435) | (143,777) | (189,644) | (160,511) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 6,810 | -- | 5,807 | (7,475) | (13,081) | (3,270) |
| Depreciation & Amortisation | 4,184 | 0.895% | 9,762 | 8,152 | 10,622 | 10,502 |
| Directors' Emoluments | -- | -- | -- | 12,911 | 35,092 | 59,696 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Qualified | Qualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | -7.000 | -53.333% | -36.000 | -41.000 | -54.000 | -46.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.416) | (0.319) | (0.431) | (0.227) |
| NBV per share ($) | 1.755 | -- | 1.827 | 2.169 | -- | -- |
| Remarks: | Real time quote last updated: 04/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -26,596 |
| %Change | -50.787% |
| EPS / (LPS) | RMB -0.070 |
| NBV Per Share (¥) | RMB 1.755 |